Zenas Biopharma, Inc. (ZBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 10, 2025, covers events occurring at Zenas Biopharma, Inc.'s 2025 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes
- Board Composition: Ting (Tim) Xiao did not stand for re-election. His term expired at the conclusion of the Annual Meeting, resulting in his resignation from the Board of Directors.
- Board Size: The Board of Directors was reduced from nine to eight members.
- Director Elections: Stockholders elected Leon O. Moulder, Jr. and Hongbo Lu, Ph.D., as Class I directors for three-year terms expiring in 2028.
- Accounting Firm: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the strategic rationale for Ting (Tim) Xiao's departure and the impact on the Board's expertise.
- Review the background and qualifications of the newly elected directors, Leon O. Moulder, Jr. and Hongbo Lu, Ph.D.
- Confirm the voting percentages: Mr. Moulder received approximately 95.6% "For" votes, while Dr. Lu received approximately 93.6% "For" votes.
- Check subsequent filings for any changes in executive compensation or corporate strategy following the Board reduction.